Natalie Rasmussen Mandolfo1, Ann M Berger1, Leeza Struwe1, Kathleen M Hanna1, Whitney Goldner2, Kelsey Klute3, Sean Langenfeld4, Marilyn Hammer5. 1. College of Nursing, Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, USA. 2. Department of Internal Medicine, Section of Diabetes, Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, USA. 3. Department of Internal Medicine, Division of Oncology & Hematology, Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, USA. 4. Department of Surgery, Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, USA. 5. Dana-Farber Cancer Institute, Boston, MA, USA.
Abstract
OBJECTIVE: To examine glycemic variability within 1 month and 1 year following surgery among adult patients, with and without Type 2 Diabetes (T2D), treated for stage II-III colon cancer. METHOD: A retrospective analysis of electronic health record data was conducted. Glycemic variability (i.e., standard deviation [SD] and coefficient of variation [CV] of > 2 blood glucose measures) was assessed within 1 month and within 1 year following colon surgery. Chi-square (χ2), Fisher's exact, and Mann-Whitney U tests were used for the analyses. RESULTS: Among the sample of 165 patients with stage II-III colon cancer, those with T2D had higher glycemic variability compared to patients without T2D (p < .001), with values within 1 month following surgery (SD = 44.69 mg/dL, CV = 27.4%) vs (SD = 20.55 mg/dL, CV = 17.53%); and within 1 year following surgery (SD = 45.04 mg/dL, CV = 29.04%) vs (SD = 21.36 mg/dL, CV = 18.6%). Associations were found between lower body mass index and higher glycemic variability (i.e., SD [r = -.413, p < .05] and CV [r = -.481, p < .01]) within 1 month following surgery in patients with T2D. Higher preoperative glucose was associated with higher glycemic variability (i.e., SD r = .448, p < .01) within 1 year in patients with T2D. Demographic and clinical characteristics were weakly associated with glycemic variability in patients without T2D. CONCLUSIONS: Patients with stage II-III colon cancer with T2D experienced higher glycemic variability within 1 month and within 1 year following surgery compared to those without T2D. Associations between glycemic variability and demographic and clinical characteristics differed by T2D status. Further research in prospective studies is warranted.
OBJECTIVE: To examine glycemic variability within 1 month and 1 year following surgery among adult patients, with and without Type 2 Diabetes (T2D), treated for stage II-III colon cancer. METHOD: A retrospective analysis of electronic health record data was conducted. Glycemic variability (i.e., standard deviation [SD] and coefficient of variation [CV] of > 2 blood glucose measures) was assessed within 1 month and within 1 year following colon surgery. Chi-square (χ2), Fisher's exact, and Mann-Whitney U tests were used for the analyses. RESULTS: Among the sample of 165 patients with stage II-III colon cancer, those with T2D had higher glycemic variability compared to patients without T2D (p < .001), with values within 1 month following surgery (SD = 44.69 mg/dL, CV = 27.4%) vs (SD = 20.55 mg/dL, CV = 17.53%); and within 1 year following surgery (SD = 45.04 mg/dL, CV = 29.04%) vs (SD = 21.36 mg/dL, CV = 18.6%). Associations were found between lower body mass index and higher glycemic variability (i.e., SD [r = -.413, p < .05] and CV [r = -.481, p < .01]) within 1 month following surgery in patients with T2D. Higher preoperative glucose was associated with higher glycemic variability (i.e., SD r = .448, p < .01) within 1 year in patients with T2D. Demographic and clinical characteristics were weakly associated with glycemic variability in patients without T2D. CONCLUSIONS: Patients with stage II-III colon cancer with T2D experienced higher glycemic variability within 1 month and within 1 year following surgery compared to those without T2D. Associations between glycemic variability and demographic and clinical characteristics differed by T2D status. Further research in prospective studies is warranted.
Authors: Yoojin Kim; Kumar B Rajan; Shannon A Sims; Kristen E Wroblewski; Sirimon Reutrakul Journal: Diabetes Res Clin Pract Date: 2014-01-03 Impact factor: 5.602
Authors: Amit Akirov; Tzipora Shochat; Idit Dotan; Talia Diker-Cohen; Alexander Gorshtein; Ilan Shimon Journal: Surgery Date: 2019-04-09 Impact factor: 3.982
Authors: Patrick Kuhlman; Scott Isom; Timothy S Pardee; Cynthia Burns; Bernard Tawfik; Zanetta S Lamar; Bayard L Powell; Heidi D Klepin Journal: Support Care Cancer Date: 2018-12-15 Impact factor: 3.603
Authors: Catherine Gorst; Chun Shing Kwok; Saadia Aslam; Iain Buchan; Evangelos Kontopantelis; Phyo K Myint; Grant Heatlie; Yoon Loke; Martin K Rutter; Mamas A Mamas Journal: Diabetes Care Date: 2015-12 Impact factor: 19.112